Biosenta Inc (ZRO) AI Stock Analysis

• Market Cap: C$3.38M
• Dividend Yield: N/A
• Average Volume (3M): 2.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.42
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -0.02
• Shares Outstanding: 33,831,387
• 10 Day Avg. Volume: 5,790
• 30 Day Avg. Volume: 2,930
• PEG Ratio: 0.02
• Price to Book (P/B): -0.33
• Price to Sales (P/S): 1878.41
• P/FCF Ratio: -3.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 26 Underperform
• Price Target: ―

Biosenta Inc's overall stock score is significantly impacted by its poor financial performance, with negative margins and high leverage being major concerns. The technical analysis suggests bearish trends, further affecting the score. The negative P/E ratio and lack of dividend yield contribute to an unattractive valuation. The absence of earnings call data or notable corporate events means these factors do not influence the score.

Positive Factors

Market Position

Biosenta's focus on antimicrobial solutions for diverse markets enhances its market position, offering resilience against sector-specific downturns.

Product Demand

Increasing demand for environmentally friendly products supports long-term revenue growth, aligning with global sustainability trends.

Revenue Model

A diversified revenue model through direct sales and partnerships enhances revenue stability and market penetration.

Negative Factors

Financial Performance

Poor financial performance and high leverage indicate financial instability, posing risks to long-term viability and growth.

Balance Sheet Health

Negative equity and high leverage suggest financial distress, limiting the company's ability to invest in growth opportunities.

Cash Flow Issues

Inability to generate positive cash flow from operations could hinder the company's capacity to sustain operations and fund future growth.

Biosenta Inc Business Overview & Revenue Model

Company Description

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.

How the Company Makes Money

Biosenta Inc makes money primarily through the sale of its antimicrobial products, which are marketed to a wide range of customers, including individual consumers, businesses, and institutions. The company's revenue model is based on direct sales as well as partnerships with distributors and retailers who help extend the reach of Biosenta's product offerings. Key revenue streams include product sales in retail locations, online marketplaces, and through direct corporate partnerships. The company's focus on environmentally friendly and effective antimicrobial solutions positions it to capitalize on growing consumer demand for safer and more sustainable cleaning products. Any significant partnerships or licensing agreements that enhance product distribution or innovation capabilities also contribute to Biosenta's earnings.

Biosenta Inc Financial Statement Overview

Summary

Biosenta Inc is experiencing significant financial challenges, with negative profitability, high leverage, and negative cash flows. The company faces significant operational inefficiencies and financial instability, indicating a need for strategic changes to improve financial health.

Income Statement

The company shows negative gross and net profit margins in the TTM, indicating it is not currently profitable. Revenue growth is low, and operating margins such as EBIT and EBITDA are significantly negative, reflecting operational inefficiencies and high operating costs relative to revenue.

Balance Sheet

The balance sheet reveals high leverage with a negative equity position, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio is negative, signaling potential financial distress. ROE is also negative, highlighting the lack of returns to shareholders.

Cash Flow

The cash flow statement shows negative operating and free cash flows, indicating the company is not generating enough cash to cover its operations. However, some improvement in free cash flow growth is noted over the periods, though it remains negative. The operating cash flow to net income ratio is negative, reflecting poor cash conversion from earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-198.15K	1.38K	1.04K	1.15K	168.10K	1.53K
Gross Profit	-198.88K	835.00	427.00	728.00	99.11K	55.00
EBITDA	-1.32M	-1.09M	-6.24M	-1.24M	-2.03M	0.00
Net Income	-2.58M	-2.23M	-6.30M	-1.46M	-2.05M	-761.91K
Balance Sheet
Total Assets	122.53K	113.54K	107.59K	256.08K	263.66K	108.83K
Cash, Cash Equivalents and Short-Term Investments	4.69K	8.53K	5.88K	27.26K	111.88K	44.31K
Total Debt	6.37M	5.55M	5.62M	94.77K	152.43K	67.45K
Total Liabilities	9.64M	7.99M	7.96M	3.18M	2.86M	1.98M
Stockholders Equity	-9.51M	-7.88M	-7.86M	-2.92M	-2.59M	-1.87M
Cash Flow
Free Cash Flow	-442.32K	-779.35K	-566.35K	-504.43K	-672.29K	-319.73K
Operating Cash Flow	-416.46K	-779.35K	-550.79K	-504.43K	-672.29K	-319.73K
Investing Cash Flow	-25.86K	0.00	-15.56K	0.00	0.00	0.00
Financing Cash Flow	440.71K	781.99K	544.97K	419.81K	739.86K	354.39K

Biosenta Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.11, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.95 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZRO.

Biosenta Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LOBE	46 Neutral	C$17.52M	-2.93	―	―	-100.00%	-8.70%
CGII	46 Neutral	C$3.29M	-1.76	―	―	-25.05%	-19.86%
BBM	42 Neutral	C$7.43M	-2.70	-150.44%	―	55.74%	-27.59%
ZRO	26 Underperform	C$3.38M	―	―	―	―	―

Biosenta Inc Corporate Events

Biosenta to Test Antimicrobial Nanoparticles in Alberta Residential Project

Biosenta Inc. has entered into a Field Test and Research Agreement with Livespace Homes to evaluate the real-world performance of its antimicrobial nanoparticle technology in a residential construction setting. This initiative aims to generate field data on performance and durability, supporting commercialization planning and broader market adoption, potentially impacting the residential construction industry by enhancing the safety and cleanliness of living spaces.